Published in J Clin Invest on January 02, 2014
DNA Methylation Indicates Susceptibility to Isoproterenol-Induced Cardiac Pathology and Is Associated With Chromatin States. Circ Res (2016) 1.44
The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget (2014) 1.12
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol (2015) 1.06
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2. J Biol Chem (2015) 1.00
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun (2016) 0.99
At the tipping point for epigenetic therapies in cancer. J Clin Invest (2014) 0.94
Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) (2015) 0.88
Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am (2014) 0.87
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. Cancer Cell (2016) 0.87
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death Dis (2014) 0.86
Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer Prevention. Biomed Res Int (2015) 0.84
SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma. Int J Biol Sci (2014) 0.84
Potential of epigenetic therapies in the management of solid tumors. Cancer Manag Res (2015) 0.83
Prospects for the development of epigenetic drugs for CNS conditions. Nat Rev Drug Discov (2015) 0.82
Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer. Oncotarget (2016) 0.81
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. Cancer Cell (2016) 0.81
Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther (2014) 0.81
Back to the future: transgenerational transmission of xenobiotic-induced epigenetic remodeling. Epigenetics (2015) 0.78
Functional AdoMet Isosteres Resistant to Classical AdoMet Degradation Pathways. ACS Chem Biol (2016) 0.78
The retinal determination gene network: from developmental regulator to cancer therapeutic target. Oncotarget (2016) 0.78
Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map? Transl Cancer Res (2016) 0.78
Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations. Expert Rev Proteomics (2015) 0.77
KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer. Oncotarget (2016) 0.77
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry. J Clin Biochem Nutr (2015) 0.76
Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. Cell Rep (2016) 0.76
The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. Mol Carcinog (2015) 0.76
Predictive value of epigenetic alterations in head and neck squamous cell carcinoma. Mol Cell Oncol (2014) 0.75
Chemical Proteomic Profiling of Human Methyltransferases. J Am Chem Soc (2016) 0.75
Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proc Natl Acad Sci U S A (2014) 0.75
HEDD: the human epigenetic drug database. Database (Oxford) (2016) 0.75
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. Biomed Res Int (2015) 0.75
Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clin Epigenetics (2015) 0.75
Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis. Proc Natl Acad Sci U S A (2017) 0.75
Environmental influences in the etiology of colorectal cancer: the premise of metabolomics. Curr Pharmacol Rep (2017) 0.75
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell (2005) 8.95
Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell (2005) 8.92
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature (1998) 7.55
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer (2011) 6.87
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Role of the polycomb protein EED in the propagation of repressive histone marks. Nature (2009) 6.62
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol (2002) 5.53
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet (2001) 3.58
The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet (2006) 3.39
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A (2012) 3.22
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene (2007) 3.19
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
Targeting epigenetic readers in cancer. N Engl J Med (2012) 2.86
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell (2010) 2.80
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
The molecular biology of mixed lineage leukemia. Haematologica (2009) 2.58
Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem (2011) 2.45
Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol (2009) 2.44
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A (2013) 2.26
Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta (2010) 2.10
The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem (2009) 2.06
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett (2012) 2.04
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol (2013) 1.89
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol (2013) 1.72
Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol (2008) 1.70
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun (2012) 1.67
Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc (2011) 1.66
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood (2007) 1.60
Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res (2009) 1.58
Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem (2012) 1.55
PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res (2013) 1.53
Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. F1000 Biol Rep (2009) 1.36
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia (2012) 1.36
Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens. J Biomol Screen (2012) 1.30
Quantitative mass spectrometry of histones H3.2 and H3.3 in Suz12-deficient mouse embryonic stem cells reveals distinct, dynamic post-translational modifications at Lys-27 and Lys-36. Mol Cell Proteomics (2010) 1.23
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One (2013) 1.19
Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma (2006) 1.14
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des (2012) 1.12
Chromosomal translocations involving the MLL gene: molecular mechanisms. DNA Repair (Amst) (2006) 1.11
Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J Med Chem (2013) 1.00
Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg Med Chem (2013) 0.99
Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase. Biochemistry (2011) 0.97
The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. Oncogene (2013) 0.96
Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem Biol (2013) 0.88
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A (2012) 3.22
A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics (2003) 2.88
A comprehensive review of thoracic deformity parameters in scoliosis. Eur Spine J (2014) 2.03
Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace (2013) 1.97
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J (2008) 1.79
Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem (2003) 1.72
The vertical expandable prosthetic titanium rib implant for the treatment of thoracic insufficiency syndrome associated with congenital and neuromuscular scoliosis in young children. J Pediatr Orthop B (2005) 1.45
Atrioventricular nodal reentrant tachycardia in children: effect of slow pathway ablation on fast pathway function. J Cardiovasc Electrophysiol (2002) 1.43
Crystal structure of the human PRMT5:MEP50 complex. Proc Natl Acad Sci U S A (2012) 1.42
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41
Growing rod techniques in early-onset scoliosis. J Pediatr Orthop (2007) 1.40
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci U S A (2006) 1.38
Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today (2005) 1.36
Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens. J Biomol Screen (2012) 1.30
Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg Med Chem Lett (2007) 1.21
Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics (2012) 1.19
Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening. Eukaryot Cell (2004) 1.19
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One (2013) 1.19
Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc (2002) 1.18
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget (2013) 1.17
Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen (2011) 1.16
Evidence for allosteric interactions of antagonist binding to the smoothened receptor. J Pharmacol Exp Ther (2009) 1.13
A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry (2006) 1.13
Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry (2007) 1.12
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett (2004) 1.07
Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP). J Biol Chem (2004) 1.06
Early onset scoliosis: future directions. J Bone Joint Surg Am (2007) 1.04
Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem (2005) 1.04
Development of a Transcreener kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. J Biomol Screen (2007) 1.04
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) (2011) 1.03
Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res Commun (2011) 1.01
An assay for Fe(II)/2-oxoglutarate-dependent dioxygenases by enzyme-coupled detection of succinate formation. Anal Biochem (2006) 1.00
Deletion of chromosome 22q11.2 and outcome in patients with pulmonary atresia and ventricular septal defect. Ann Thorac Surg (2003) 1.00
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. Biochem J (2009) 0.98
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. J Med Chem (2004) 0.98
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol (2008) 0.96
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem (2010) 0.92
Warning symptoms and family history in children and young adults with sudden cardiac arrest. J Am Board Fam Med (2012) 0.91
Characterization of an exosite binding inhibitor of matrix metalloproteinase 13. Protein Sci (2007) 0.90
Weight gain following vertical expandable prosthetic titanium ribs surgery in children with thoracic insufficiency syndrome. Spine (Phila Pa 1976) (2009) 0.89
Myocardial infarction in adolescents. J Pediatr (2007) 0.89
Use of a biodegradable patch for reconstruction of large thoracic cage defects in growing children. J Pediatr Surg (2006) 0.89
Vertical expandable prosthetic titanium rib as treatment of thoracic insufficiency syndrome in spondylocostal dysplasia. J Pediatr Orthop (2010) 0.89
Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem Biol (2013) 0.88
Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest (2015) 0.87
Targeting enzyme inhibitors in drug discovery. Expert Opin Ther Targets (2007) 0.87
A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res (2012) 0.87
Determining lung volume with three-dimensional reconstructions of CT scan data: A pilot study to evaluate the effects of expansion thoracoplasty on children with severe spinal deformities. J Pediatr Orthop (2004) 0.87
Fusionless procedures for the management of early-onset spine deformities in 2011: what do we know? J Child Orthop (2011) 0.87
Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment Cell Melanoma Res (2014) 0.87
Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J Med Chem (2005) 0.86
Natural history and current therapy for complete heart block in children and patients with congenital heart disease. Congenit Heart Dis (2008) 0.86
Efficacy of intraoperative neurologic monitoring in surgery involving a vertical expandable prosthetic titanium rib for early-onset spinal deformity. J Bone Joint Surg Am (2009) 0.86
Adjunctive vancomycin powder in pediatric spine surgery is safe. Spine (Phila Pa 1976) (2013) 0.85
C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site. Arch Biochem Biophys (2010) 0.85
Mortality and life-threatening events after vertical expandable prosthetic titanium rib surgery in children with hypoplastic chest wall deformity. J Pediatr Orthop (2008) 0.85
Acute pacing-induced dyssynchronous activation of the left ventricle creates systolic dyssynchrony with preserved diastolic synchrony. J Cardiovasc Electrophysiol (2008) 0.84
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. Bioorg Med Chem Lett (2003) 0.83
Congenital scoliosis. Med Sci Monit (2004) 0.83
Health care utilization and psychosocial factors in pediatric noncardiac chest pain. Health Psychol (2012) 0.83
Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites. Biochem J (2011) 0.83
Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis. Biochemistry (2008) 0.83
Magnetically controlled growing rods for spinal deformity. Lancet (2012) 0.82
Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator. J Am Chem Soc (2008) 0.81
Health-related quality of life in children with thoracic insufficiency syndrome. J Pediatr Orthop (2008) 0.81
The catalytic role of INCENP in Aurora B activation and the kinetic mechanism of Aurora B/INCENP. Biochem J (2009) 0.81
Natural history of thoracic insufficiency syndrome: a spondylothoracic dysplasia perspective. J Bone Joint Surg Am (2007) 0.81
Helicobacter pylori 3-deoxy-D-manno-octulosonate-8-phosphate (KDO-8-P) synthase is a zinc-metalloenzyme. Biochim Biophys Acta (2002) 0.81
Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines. Bioorg Med Chem Lett (2004) 0.80
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines. Mol Cancer Ther (2004) 0.80
Effects of single-site versus biventricular epicardial pacing on myocardial performance in an immature animal model of atrioventricular block. J Cardiovasc Electrophysiol (2006) 0.80
Outcomes following electroanatomic mapping and ablation for the treatment of ectopic atrial tachycardia in the pediatric population. Pediatr Cardiol (2007) 0.80
Corrigendum: The promise and peril of chemical probes. Nat Chem Biol (2015) 0.79
Glioma-propagating cells as an in vitro screening platform: PLK1 as a case study. J Biomol Screen (2012) 0.79
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. Bioorg Med Chem Lett (2003) 0.79
The development of potent and selective bisarylmaleimide GSK3 inhibitors. Bioorg Med Chem Lett (2005) 0.79
Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay. Anal Biochem (2008) 0.79
Evaluating the extent of clinical uncertainty among treatment options for patients with early-onset scoliosis. J Bone Joint Surg Am (2013) 0.79
Catheter ablation of primary supraventricular tachycardia substrate presenting as atrial fibrillation in adolescents. Congenit Heart Dis (2010) 0.78
Management of Thoracic Insufficiency Syndrome in Patients With Jeune Syndrome Using the 70 mm Radius Vertical Expandable Prosthetic Titanium Rib. J Pediatr Orthop (2015) 0.78
Development of a microplate-based, electrophoretic fluorescent protein kinase a assay: comparison with filter-binding and fluorescence polarization assay formats. J Biomol Screen (2005) 0.78
Long-term risk of fatal malignancy following pediatric radiofrequency ablation. Am J Cardiol (2008) 0.78
Evaluation of myocardial performance with conventional single-site ventricular pacing and biventricular pacing in a canine model of atrioventricular block. J Cardiovasc Electrophysiol (2003) 0.77
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation. Bioorg Med Chem Lett (2004) 0.76
Radiofrequency modification for inducible and suspected pediatric atrioventricular nodal reentry tachycardia. J Interv Card Electrophysiol (2005) 0.76
Response to "...spondylothoracic dysplasia syndrome: a series of 27 new cases" by Cornier et al. Am J Med Genet A (2004) 0.75
Brief report: Psychosocial factors and pediatric noncardiac chest pain. J Pediatr Psychol (2009) 0.75
Approaches for the very young child with spinal deformity: what's new and what works. Instr Course Lect (2010) 0.75
Internalizing symptoms and functional disability in children with noncardiac chest pain and innocent heart murmurs. J Pediatr Psychol (2012) 0.75
VEPTR to treat nonsyndromic congenital scoliosis: a multicenter, mid-term follow-up study. J Pediatr Orthop (2013) 0.75
Infection Control in Pediatric Spinal Deformity Surgery: A Systematic and Critical Analysis Review. JBJS Rev (2017) 0.75
Sudden cardiac death in children and adolescents: introduction and overview. Pacing Clin Electrophysiol (2009) 0.75
Site-specific Surgical Site Infection Rates for Rib-based Distraction. J Pediatr Orthop (2019) 0.75
Parent and child psychological factors in pediatric syncope and other somatic symptoms. J Consult Clin Psychol (2004) 0.75